A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

References

• Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, . Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 2008;371(9606):29–40.
   PubMedGoogle Scholar
• Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352(9132):930–42.
   PubMedGoogle Scholar
• Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166–70.
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, . Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–13.
   PubMed Web of Science ®Google Scholar
• Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, . Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006;24: 5664–71.
   PubMed Web of Science ®Google Scholar
• Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, . Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381–7.
   PubMed Web of Science ®Google Scholar
• Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007(4):CD004421.
   Google Scholar
• Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, . Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805–14.
   PubMedGoogle Scholar
• Sandstrom M, Freijs A, Larsson R, Nygren P, Fjallskog ML, Bergh J, . Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581–8.
   PubMed Web of Science ®Google Scholar
• Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, . Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007;18:694–700.
   PubMed Web of Science ®Google Scholar
• Bonnefoi HR, Bogaerts J, Piccart M, Mauriac L, Fumoleau P, Jassem J, . Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. 2010 ASCO Annual Meeting; 2010. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA503); 2010.
   Google Scholar
• Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, . Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–9.
   PubMed Web of Science ®Google Scholar
• Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, . Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J Clin Oncol 2010;28:2874–80.
   PubMed Web of Science ®Google Scholar
• Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, . Dose-dense adjuvant chemotherapy in node-positive breast cancer: Docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007;18:52–7.
   PubMedGoogle Scholar
• Di Leo A, Crown J, Nogaret JM, Duffy K, Bartholomeus S, Dolci S, . A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 2000;11:169–75.
   PubMedGoogle Scholar
• Schwartz J, Domchek SM, Hwang WT, Fox K. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005;16:247–52.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Forceville K, Paridaens R, Joensuu H. Taxanes and anthracyclines in early breast cancer: Which first? Lancet Oncol 2010;11:219–20.
   PubMedGoogle Scholar
• Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, . Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205–11.
   PubMed Web of Science ®Google Scholar
• Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837–42.
   PubMed Web of Science ®Google Scholar
• Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763–6.
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301–5.
   PubMed Web of Science ®Google Scholar
• Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913–21.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Peeters M, Humblet Y, Vermorken JB, De Hertogh G, De Roock W, . Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). In: ASCO; 2008: JCO; 2008. p. Abstract 4001.
   Google Scholar
• Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 2008;9:1143–8.
   PubMed Web of Science ®Google Scholar
• Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, . Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004;10:5754–61.
   PubMed Web of Science ®Google Scholar